Key Trends in the Political and Reimbursement Environment for Cancer Drugs

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• United States
  • Changes to Medicare Part D Coverage of Oncology Drugs
  • Impact of Changes to Medicare Part B Reimbursement
  • Reductions in Medicare Hospital Outpatient Reimbursement
  • Reimbursement Changes in the Private Sector
  • Infl uence of Physician Reimbursement on Prescribing Behavior
  • Coverage of Targeted Therapies
  • Cost-Containment Strategies
  • Patient Access to Innovative Therapies
  • Courts Reject Calls for Right of Access to Experimental Drugs
  • FDA Amendments Act
• France
  • Strong Growth in Spending on Oncology Drugs
  • Flexible Funding Arrangements for Innovative Drugs
  • Promoting Good Use of Cancer Therapies
• Germany
  • Prospect of Health Economic Evaluation and Reimbursement Limits for New Therapies
  • Interaction Between Hospitals and Primary Care
  • Disease Management Programs
  • Off-Label Prescribing
• Italy
  • Hospital Reimbursement
  • Financial Constraints
• Spain
  • Regional Variations in the Use of Innovative Therapies
  • National Cancer Strategy
  • Future Emphasis on Health Technology Assessment of New Drugs
• United Kingdom
  • Cancer Reform Strategy
  • NICE' s Impact on U.K. Oncology
  • Diffi culties of Combining Privately and Publicly Funded Treatment
  • Government Plans to Replace the Pharmaceutical Price Regulation Scheme
• Outlook and Implications for the Pharmaceutical Industry

Tables

• 1. Regional Variations in the Use of Select Targeted Cancer Therapies in Spain

Figures

• 1. U.S. Cancer Patients' Principal Sources of Health Insurance Coverage
• 2. Coverage of Select Targeted Cancer Therapies by Private Health Plan
• 3. Coverage of Select Targeted Cancer Therapies by Medicare Plans
• 4. Percentage of Private and Medicare Plans That Impose Prior Authorization on Select Targeted Cancer Therapies
• 5. Percentage of Private and Medicare Plans That Monitor Patient Response to Select Targeted Cancer Therapies
• 6. Percentage of Private and Medicare Plans That Impose Quantity Limits on Select Targeted Cancer Therapies
• 7. Percentage of Private and Medicare Plans That Require Patients to Obtain Select Targeted Cancer Therapies from Specialty Pharmacies
• 8. Percentage of Private and Medicare Plans That Impose No Cost Controls on the Use of Select Targeted Cancer Therapies

Sidebar

• Brown Bagging on the Increase in the United States